Stocktoria

REGENXBIO Inc. RGNX

Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-09-17
Chart by TradingView
3/9
Piotroski F — financial health
-7.82
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$170.4M$83.3M$90.2M$112.7M$470.3M
Operating income-$161.2M-$233.3M-$268.1M-$262.9M$160.0M
Net income-$193.9M-$227.1M-$263.5M-$280.3M$127.8M
Operating cash flow-$124.0M-$173.1M-$218.4M-$207.5M$218.9M
Free cash flow-$126.4M-$175.6M-$228.4M-$238.2M$134.7M
Total assets$453.0M$466.0M$574.0M$833.3M$1.1B
Total liabilities$350.3M$206.3M$262.2M$317.1M$349.6M
Shareholders' equity$102.7M$259.7M$311.7M$516.2M$764.3M
Ratios
Operating margin-94.6%-280.0%-297.1%-233.2%34.0%
Net margin-113.8%-272.5%-292.0%-248.7%27.2%
FCF margin-74.1%-210.7%-253.1%-211.3%28.6%
Return on assets-42.8%-48.7%-45.9%-33.6%11.5%
Return on equity-188.7%-87.5%-84.5%-54.3%16.7%
Current ratio2.382.692.573.193.98
Revenue growth104.5%-7.7%-19.9%-76.0%204.3%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC305,286$2.6M
Point72 Asset Management, L.P.139,791$1.2M

Why these scores methodology →

Piotroski F-score: 3/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -7.82 (distress)

  • Working capital / assets 0.36
  • Retained earnings / assets -2.486
  • EBIT / assets -0.356
  • Equity / liabilities 0.293

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001590877 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.